AstraZeneca Current Ratio 2010-2024 | AZN

Current and historical current ratio for AstraZeneca (AZN) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. AstraZeneca current ratio for the three months ending March 31, 2024 was 0.89.
AstraZeneca Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2024-03-31 $25.59B $28.90B 0.89
2023-12-31 $25.05B $30.54B 0.82
2023-09-30 $22.50B $28.59B 0.79
2023-06-30 $22.84B $26.38B 0.87
2023-03-31 $22.27B $24.86B 0.90
2022-12-31 $22.59B $26.29B 0.86
2022-09-30 $20.22B $24.85B 0.81
2022-06-30 $20.92B $21.82B 0.96
2022-03-31 $22.65B $22.74B 1.00
2021-12-31 $26.24B $22.59B 1.16
2021-09-30 $26.69B $23.65B 1.13
2021-06-30 $27.27B $22.22B 1.23
2021-03-31 $18.74B $21.51B 0.87
2020-12-31 $19.54B $20.31B 0.96
2020-09-30 $18.17B $18.94B 0.96
2020-06-30 $14.93B $18.18B 0.82
2020-03-31 $12.82B $17.04B 0.75
2019-12-31 $15.56B $18.12B 0.86
2019-09-30 $13.52B $14.78B 0.92
2019-06-30 $15.22B $16.03B 0.95
2019-03-31 $13.65B $18.26B 0.75
2018-12-31 $15.59B $16.29B 0.96
2018-09-30 $13.11B $15.25B 0.86
2018-06-30 $12.45B $17.20B 0.72
2018-03-31 $13.18B $18.16B 0.73
2017-12-31 $13.15B $16.38B 0.80
2017-09-30 $13.63B $14.46B 0.94
2017-06-30 $14.30B $15.66B 0.91
2017-03-31 $11.64B $15.43B 0.75
2016-12-31 $13.26B $15.26B 0.87
2016-09-30 $12.87B $15.38B 0.84
2016-06-30 $13.32B $14.34B 0.93
2016-03-31 $12.77B $15.93B 0.80
2015-12-31 $16.01B $14.87B 1.08
2015-09-30 $13.20B $16.04B 0.82
2015-06-30 $13.81B $16.15B 0.86
2015-03-31 $12.69B $15.76B 0.81
2014-12-31 $16.70B $17.33B 0.96
2014-09-30 $15.07B $15.82B 0.95
2014-06-30 $16.20B $16.32B 0.99
2014-03-31 $16.54B $17.51B 0.95
2013-12-31 $20.34B $16.05B 1.27
2013-09-30 $18.79B $14.68B 1.28
2013-06-30 $19.39B $15.20B 1.28
2013-03-31 $18.34B $13.86B 1.32
2012-12-31 $19.05B $13.90B 1.37
2012-09-30 $18.03B $14.13B 1.28
2012-06-30 $19.78B $14.80B 1.34
2012-03-31 $21.56B $15.80B 1.37
2011-12-31 $23.51B $15.75B 1.49
2011-09-30 $22.47B $14.66B 1.53
2011-06-30 $22.69B $13.84B 1.64
2011-03-31 $23.47B $16.02B 1.47
2010-12-31 $25.13B $16.79B 1.50
2010-09-30 $24.57B $16.85B 1.46
2010-06-30 $23.38B $16.30B 1.43
2010-03-31 $22.35B $16.99B 1.32
2009-12-31 $23.76B $17.64B 1.35
2009-09-30 $20.54B $15.12B 1.36
2009-06-30 $19.13B $15.14B 1.26
2009-03-31 $15.85B $14.05B 1.13
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $248.255B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $824.287B 119.14
Novo Nordisk (NVO) Denmark $642.884B 49.40
Johnson & Johnson (JNJ) United States $349.955B 13.90
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
Novartis AG (NVS) Switzerland $215.744B 15.30
Pfizer (PFE) United States $156.738B 19.48
Sanofi (SNY) $122.543B 11.56
Innoviva (INVA) United States $0.993B 6.97